• Dr. Graham Taylor: Understanding and Combatting HTLV-1丨ECCMID 2023

    HTLV-1, a retrovirus closely associated with certain forms of cancer, remains a lesser-known but significant global health concern. Despite its considerable impact on populations around the world, there is a lack of attention and understanding regarding this infection. This article sheds light on the challenges posed by HTLV-1 and emphasizes the need for increased awareness,…

  • Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

    Antimicrobial susceptibility testing (AST) is pivotal in both individualized and empirical treatments. Notably, standards set for interpreting AST results enable clinicians to choose suitable medications and optimal treatment plans, acting as a significant tool in controlling antimicrobial resistance. The most influential bodies in this space are the Clinical and Laboratory Standards Institute (CLSI) of the…

  • Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

    Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference (…

  • Dr. Hui Wang: Second-line treatment choice for children with HIV infection

    Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections.…

  • Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

    The concept of rapid initiation of antiretroviral therapy (ART) has been proposed for nearly 10 years, and many studies have confirmed the long-term benefits of rapid ART initiation. At the 12th International AIDS Society HIV Science Conference (IAS 2023), Thai scholar Sirinya Teeraananchai reported a study on the impact of rapid ART initiation on the…

  • Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

    The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy…

  • Interview with Dr. Melissa L. Johnson at WCLC 2023

    The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University’s Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the…

  • Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

    The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more “efficient and less toxic” treatment options to improve patients’ quality of life.…